|By PR Newswire||
|April 15, 2014 10:17 AM EDT||
CHICAGO, April 15, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the name Rasuvo™ for the company's lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen.
Currently under FDA review, Rasuvo is being developed for multiple indications, including rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis, and is designed to improve bioavailability and overcome tolerability issues associated with today's oral MTX therapies. Medac Pharma plans to offer Rasuvo in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments.
"Securing name approval for our lead compound is another important milestone as we prepare for a potential U.S. launch of Rasuvo later this year," said Ms. Terri Shoemaker, President and CEO of Medac Pharma, Inc. "With its planned 10 dosage strengths and ease of administration, Rasuvo is well-positioned to offer patients an optimal therapeutic option for managing rheumatoid arthritis and other related diseases as our product will offer the widest range of dosing options compared to other subcutaneous methotrexate therapies."
About Medac Pharma, Inc.
Medac Pharma, Inc. is the wholly-owned subsidiary of medac GmbH, a well-known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.
Medac Pharma, Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives. The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.
For more information, please visit www.medacpharma.com.
SOURCE Medac Pharma, Inc.
Aug. 30, 2016 06:15 PM EDT Reads: 326
Aug. 30, 2016 05:45 PM EDT Reads: 3,585
Aug. 30, 2016 05:00 PM EDT Reads: 891
Aug. 30, 2016 04:15 PM EDT Reads: 959
Aug. 30, 2016 03:30 PM EDT Reads: 3,775
Aug. 30, 2016 03:00 PM EDT Reads: 852
Aug. 30, 2016 02:30 PM EDT Reads: 1,039
Aug. 30, 2016 02:30 PM EDT Reads: 953
Aug. 30, 2016 02:00 PM EDT Reads: 3,778
Aug. 30, 2016 01:45 PM EDT Reads: 656
Aug. 30, 2016 01:30 PM EDT Reads: 870
Aug. 30, 2016 01:20 PM EDT Reads: 270
Aug. 30, 2016 01:15 PM EDT Reads: 2,067
Aug. 30, 2016 01:00 PM EDT Reads: 3,235
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Aug. 30, 2016 11:45 AM EDT Reads: 804